A new buy for aggressive investors

This month, we’re adding Danaher to our Aggressive Growth Portfolio. This maker of specialized measuring equipment and tools is a long-time recommendation of our TSI Spinoffs and Takeovers newsletter, which focuses on spinoffs and their former parent companies.
Danaher has completed three spinoffs since July 2016. Since then,… Read More

Long dividend histories add to their appeal

Both of these U.S. firms have a long history of rewarding investors with annual dividend increases. Notably, each is a leader in its industry, which further cuts your risk.
PFIZER INC. $45 is a buy. The company (New York symbol PFE; Income-Growth Dividend Payer Portfolio, Manufacturing sector; Shares… Read More

Key move for Merck

MERCK & CO. INC., $93.26, is a #1 Power Buy for 2022. The drugmaker (New York symbol MRK; TSINetwork Rating: Above Average) (www.merck.com; Shares outstanding: 2.5 billion; Market cap: $239.7 billion; Dividend yield: 3.0%) has now exercised an option to jointly develop and potentially sell an mRNA-based cancer vaccine along… Read More

Lilly targets RNA medicines

ELI LILLY & CO., $276.44, is a buy. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares o/s: 952.3 million; Market cap: $262.3 billion; Dividend yield: 1.4%) has announced that it’s building a new RNA medicine centre in Boston for $700 million. Eli Lilly’s investment in… Read More